At a glance
- Originator Lundbeck A/S; Merck KGaA
- Class Antipsychotics; Dibenzazepines; Small molecules
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 18 Jan 2001 Discontinued-Preclinical for Schizophrenia in Netherlands (Unknown route)
- 14 Dec 1999 New profile
- 14 Dec 1999 Preclinical development for Schizophrenia in Netherlands (Unknown route)